BioLight’s New Investment in Sanoculis Ltd., a medical device company which develops an innovative surgical procedure for the ab-interno treatment of the Glaucoma

Tel Aviv (September 11, 2019) – BioLight is pleased to announce that today, it has signed a binding agreement, together with Mr. Zohar Zisapel, for its investment in Sanoculis Ltd. (the “Agreement” and “Sanoculis”). According to the Agreement, BioLight shall invest approx. USD 1.1M out of a total investment and loans’ conversions of up to USD 3m (the “Total Investment”). Assuming Total Investment, the Company shall hold approx. 5% of the issued and fully paid up share capital of Sanoculis on a fully diluted basis.


Link to the complete article

Link to Newsroom

Comments are closed.